3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
2
CNS
2
Sarcoma
1
NET
1
Conditions
Sarcoma
9
Osteosarcoma
4
Sarcoma, Ewing
3
Rhabdomyosarcoma
3
Neuroblastoma
3
Neoplasms
3
Medulloblastoma
3
Glioma
3
Ependymoma
3
Central Nervous System Neoplasms
3
Carcinosarcoma
3
Wilms Tumor
2
Rhabdoid Tumor
2
Recurrence
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neoplasm Metastasis
2
Lymphoma, Non-Hodgkin
2
Histiocytosis, Langerhans-Cell
2
Hepatoblastoma
2
Glioblastoma
2
Endometrial Neoplasms
2
Carcinoma, Endometrioid
2
Breast Neoplasms
2
Xanthogranuloma, Juvenile
1
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Sarcoma, Synovial
1
Prostatic Neoplasms
1
Pheochromocytoma
1
Pathologic Complete Response
1
Interventions
Radiotherapy
3
Doxorubicin
3
Ifosfamide
2
Filgrastim
2
tipifarnib
1
olaparib
1
lutetium Lu 177 dotatate
1
guadecitabine
1
Tamoxifen
1
Specimen Handling
1
Ritonavir
1
Quality of Life
1
Patient Reported Outcome Measures
1
Oxaliplatin
1
Nivolumab
1
Molecular Diagnostic Techniques
1
Magnetic Resonance Spectroscopy
1
Leucovorin
1
Ipilimumab
1
Indinavir
1
Immunotherapy
1
Genetic Testing
1
Fluorodeoxyglucose F18
1
Floxuridine
1
Drug Therapy
1
Cisplatin
1
Chemotherapy, Adjuvant
1
CTLA-4 Antigen
1
Biological Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pheochromocytoma
×
olaparib
×
Sarcoma
×
Clear all
NCT06607692
2026-06-04
LUPARPED
Fundación de investigación HM
Phase 1/2
Recruiting
25 enrolled